Gastrointestinal diseases are a significant health care and economic burden. Prevention and treatment of these diseases have been limited by the available human biologic models. Microphysiological systems comprise organ-specific human cultures that recapitulate many structural, biological, and functional properties of the organ in smaller scale including aspects of flow, shear stress and chemical gradients. The development of intestinal microphysiological system platforms represents a critical component in improving our understanding, prevention, and treatment of gastrointestinal diseases. This minireview discusses: shortcomings of classical cell culture models of the gastrointestinal tract; human intestinal enteroids as a new model and their advantages compared to cell lines; why intestinal microphysiological systems are needed; potential functional uses of intestinal microphysiological systems in areas of drug development and modeling acute and chronic diseases; and current challenges in the development of intestinal microphysiological systems.
Impact statement
The development of a gastrointestinal MPS has the potential to facilitate the understanding of GI physiology. An ultimate goal is the integration of the intestinal MPS with other organ MPS. The development and characterization of nontransformed human intestinal cultures for use in MPS have progressed significantly since the inception of the MPS program in 2012, and these cultures are a key component of advancing MPS. Continued efforts are needed to optimize MPS to comprehensively and accurately recapitulate the complexity of the intestinal epithelium within intestinal tissue. These systems will need to include peristalsis, flow, and oxygen gradients, with incorporation of vascular, immune, and nerve cells. Regional cellular organization of crypt and villus areas will also be necessary to better model complete intestinal structure.
BenamKHDauthSHassellBHerlandAJainAJangKJKaralisKKimHJMacQueenLMahmoodianRet al.Engineered in vitro disease models. Ann Rev Pathol2015; 10: 195–262.
2.
SatoTVriesRGSnippertHJvan de WeteringMBarkerNStangeDEvan EsJHAboAKujalaPPetersPJet al.Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature2009; 459: 262–5.
3.
PeeryAFDellonESLundJCrockettSDMcGowanCEBulsiewiczWJGangarosaLMThinyMTStizenbergKMorganDRet al.Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology2012; 143: 1179–87.
4.
Le FE, Chesne C, Artusson P, Brayden D, Fabre G, Gires P, Guillou F, Rousset M, Rubas W, Scarino ML. In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods. Altern Lab Anim2001; 29: 649–68.
5.
KutukOLetaiA. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res2008; 68: 7985–94.
6.
AwortweCFasinuPSRosenkranzB. Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges. J Pharm Pharm Sci2014; 17: 1–19.
7.
LarregieuCABenetLZ. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. AAPS J2013; 15: 483–97.
8.
SunDLennernasHWelageLSBarnettJLLandowskiCPFosterDFleisherDLeeKDAmidonGL. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res2002; 19: 1400–16.
9.
LeonardFCollnotEMLehrCM. A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro. Mol Pharm2010; 67: 2103–19.
10.
NollevauxGDevilleCElMBZorziWDeloyerPSchneiderYJPeulenODandrifosseG. Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21). BMC Cell Biol2006; 7: 20–20.
11.
HilgendorfCSpahn-LangguthHRegardhCGLipkaEAmidonGLLangguthP. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci2000; 89: 63–75.
12.
EganWJLauriG. Prediction of intestinal permeability. Adv Drug Deliv Rev2002; 54: 273–89.
13.
EschEWBahinskiAHuhD. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov2015; 14: 248–60.
14.
AhmedSSRamakrishnanV. Systems biological approach of molecular descriptors connectivity: optimal descriptors for oral bioavailability prediction. PLoS One2012; 7: e40654–e40654.
15.
HeikkinenATKorjamoTMonkkonenJ. Modelling of drug disposition kinetics in in vitro intestinal absorption cell models. Basic Clin Pharmacol Toxicol2010; 106: 180–8.
16.
HackamDGRedelmeierDA. Translation of research evidence from animals to humans. JAMA2006; 296: 1731–2.
17.
Martic-KehlMISchibliRSchubigerPA. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imag2012; 39: 1492–6.
18.
MestasJHughesCC. Of mice and not men: differences between mouse and human immunology. J Immunol2004; 172: 2731–8.
19.
WarrenHSTompkinsRGMoldawerLLSeokJXuWMindrinosMNMaierRVXiaoWDavisRW. Mice are not men. Proc Natl Acad Sci U S A2015; 112: E345–E345.
20.
SpenceJRMayhewCNRankinSAKuharMFVallanceJETolleKHoskinsEEKalinichenkoVVWellsSIZornAMet al.Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature2011; 470: 105–9.
21.
SatoTStangeDEFerranteMVriesRGvan EsJHVan den BrinkSVan HoudtWJPronkAVanGJSiersemaPDet al.Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology2011; 141: 1762–72.
22.
ZachosNCKovbasnjukOFoulke-AbelJInJBluttSEde JongeHREstesMKDonowitzM. Human enteroids/colonoids and intestinal organoids functionally recapitulate normal intestinal physiology and pathophysiology. J Biol Chem2016; 291: 3759–66.
23.
InJGFoulke-AbelJEstesMKZachosNCKovbasnjukODonowitzM. Human mini-guts: new insights into intestinal physiology and host-pathogen interactions. Nat Rev Gastroenterol Hepatol2016; 13: 633–42.
24.
MillsMEstesMK. Physiologically relevant human tissue models for infectious diseases. Drug Discov Today2016; 21: 1540–52.
25.
AuroraMSpenceJR. hPSC-derived lung and intestinal organoids as models of human fetal tissue. Dev Biol2016; 420: 230–8.
26.
FinkbeinerSRHillDRAltheimCHDedhiaPHTaylorMJTsaiYHChinAMMaheMMWatsonCLFreemanJJet al.Transcriptome-wide analysis reveals hallmarks of human intestine development and maturation in vitro and in vivo. Stem Cell Rep2015; 4: 1140–55.
27.
SatoTCleversH. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science2013; 340: 1190–4.
28.
Foulke-AbelJInJYinJZachosNCKovbasnjukOEstesMKdeJHDonowitzM. Human enteroids as a model of upper small intestinal ion transport physiology and pathophysiology. Gastroenterology2016; 150: 638–49.
29.
MiddendorpSSchneebergerKWiegerinckCLMokryMAkkermanRDvanWSCleversHNieuwenhuisEE. Adult stem cells in the small intestine are intrinsically programmed with their location-specific function. Stem Cells2014; 32: 1083–91.
30.
IngberDE. Reverse engineering human pathophysiology with organs-on-chips. Cell2016; 164: 1105–9.
31.
HuhDMatthewsBDMammotoAMontoya-ZavalaMHsinHYIngberDE. Reconstituting organ-level lung functions on a chip. Science2010; 328: 1662–8.
32.
HuhDKimHJFraserJPSheaDEKhanMBahinskiAHamiltonGAIngberDE. Microfabrication of human organs-on-chips. Nat Protoc2013; 8: 2135–57.
van der MeerADvan den BergA. Organs-on-chips: breaking the in vitro impasse. Integr Biol2012; 4: 461–70.
35.
FlaimCJChienSBhatiaSN. An extracellular matrix microarray for probing cellular differentiation. Nat Meth2005; 2: 119–25.
36.
BerthierEYoungEWBeebeD. Engineers are from PDMS-land, Biologists are from Polystyrenia. LabChip2012; 12: 1224–37.
37.
ChungBGLeeKHKhademhosseiniALeeSH. Microfluidic fabrication of microengineered hydrogels and their application in tissue engineering. Lab Chip2012; 12: 45–59.
38.
SeliktarD. Designing cell-compatible hydrogels for biomedical applications. Science2012; 336: 1124–8.
39.
HuangGYZhouLHZhangQCChenYMSunWXuFLuTJ. Microfluidic hydrogels for tissue engineering. Biofabrication2011; 3: 012001–012001.
40.
GjorevskiNSachsNManfrinAGigerSBraginaMEOrdonez-MoranPCleversHLutolfMP. Designer matrices for intestinal stem cell and organoid culture. Nature2016; 539: 560–4.
41.
KwapiszewskaKMichalczukARybkaMKwapiszewskiRBrzozkaZ. A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening. Lab Chip2014; 14: 2096–104.
42.
ZiolkowskaKStelmachowskaAKwapiszewskiRChudyMDybkoABrzozkaZ. Long-term three-dimensional cell culture and anticancer drug activity evaluation in a microfluidic chip. Biosens Bioelectron2013; 40: 68–74.
43.
SakolishCMEschMBHickmanJJShulerMLMahlerGJ. Modeling barrier tissues in vitro: methods, achievements, and challenges. EBioMedicine2016; 5: 30–9.
44.
KimHJIngberDE. Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr Biol2013; 5: 1130–40.
45.
EschMBMahlerGJStokolTShulerML. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip2014; 14: 3081–92.
46.
WangXYamamotoYWilsonLHZhangTHowittBEFarrowMAKernFNingGHongYKhorCCet al.Cloning and variation of ground state intestinal stem cells. Nature2015; 522: 173–8.
47.
VanDussenKLMarinshawJMShaikhNMiyoshiHMoonCTarrPICiorbaMAStappenbeckTS. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut2015; 64: 911–20.
48.
EttayebiKCrawfordSEMurakamiKBroughmanJRKarandikarUTengeVRNeillFHBluttSEZengXLQuLet al.Replication of human noroviruses in stem cell-derived human enteroids. Science2016; 353: 1387–93.
49.
InJFoulke-AbelJZachosNCHansenAMKaperJBBernsteinHDHalushkaMBluttSEstesMKDonowitzMet al.Enterohemorrhagic Escherichia coli reduce mucus and intermicrovillar bridges in human stem cell-derived colonoids. Cell Mol Gastroenterol Hepatol2016; 2: 48–62.
50.
TamDTironaRGPangKS. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos2003; 31: 373–83.
51.
MahlerGJEschMBGlahnRPShulerML. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnol Bioeng2009; 104: 193–205.
52.
WikswoJPCurtisELEagletonZEEvansBCKoleAHofmeisterLHMatloffWJ. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip2013; 13: 3496–511.
53.
ImuraYSatoKYoshimuraE. Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism, and bioactivity. Anal Chem2010; 82: 9983–8.
54.
ImuraYYoshimuraESatoK. Micro total bioassay system for oral drugs: evaluation of gastrointestinal degradation, intestinal absorption, hepatic metabolism, and bioactivity. Anal Sci2012; 28: 197–9.
55.
ProtJMMacielLBricksTMerlierFCottonJPaullierPBoisFYLeclercE. First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans. Biotechnol Bioeng2014; 111: 2027–40.
56.
HubatschIRagnarssonEGArturssonP. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc2007; 2: 2111–9.
57.
TaipalensuuJTornblomHLindbergGEinarssonCSjoqvistFMelhusHGarbergPSjostromBLundgrenBArturssonP. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther2001; 299: 164–70.
58.
GrabingerTLuksLKostadinovaFZimberlinCMedemaJPLeistMBrunnerT. Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy. Cell Death Dis2014; 5: e1228–e1228.
59.
GaoDLiuHLinJMWangYJiangY. Characterization of drug permeability in Caco-2 monolayers by mass spectrometry on a membrane-based microfluidic device. Lab Chip2013; 13: 978–85.
60.
VernettiLGoughABaetzNBluttSEBroughmanJR.BrownJAFoulke-AbelJHasanNInJKellyEKovbasnjukORepperJSenutovitchNStabbJYeungCZachosNCDonowitzMEstesMHimmelfarbJTruskeyGWikswoJPTaylorDL. Functional coupling of human microphysiology systems: intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle. Sci Rep2017; 7: 42296–42296.
61.
SaxenaKBluttSEEttayebiKZengXLBroughmanJRCrawfordSEKarandikarUCSastriNPConnerMEOpekunARet al.Human intestinal enteroids: a new model to study human rotavirus infection, host restriction, and pathophysiology. J Virol2015; 90: 43–56.
62.
SeokJWarrenHSCuencaAGMindrinosMNBakerHVXuWRichardsDRMcDonald-SmithGPGaoHHennessyLet al.Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A2013; 110: 3507–12.
63.
JiminezJAUwieraTCDouglasIGUwieraRR. Animal models to study acute and chronic intestinal inflammation in mammals. Gut Pathog2015; 7: 29–29.
64.
AvitzurYGuoCMastropaoloLABahramiEChenHZhaoZElkadriADhillonSMurchieRFattouhRet al.Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. Gastroenterology2014; 146: 1028–39.
65.
CutlerDJZwickMEOkouDTPrahaladSWaltersTGutherySLDubinskyMBaldassanoRCrandallWVRoshJet al.Dissecting allele architecture of early onset ibd using high-density genotyping. PLoS One2015; 10: e0128074–e0128074.
66.
GraczADWilliamsonIARocheKCJohnstonMJWangFWangYAttayekPJBalowskiJLiuXFLaurenzaRJet al.A high-throughput platform for stem cell niche co-cultures and downstream gene expression analysis. Nat Cell Biol2015; 17: 340–9.
67.
OgawaMOgawaSBearCEAhmadiSChinSLiBGrompeMKellerGKamathBMGhanekarA. Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat Biotechnol2015; 33: 853–61.
68.
SkardalADevarasettyMForsytheSAtalaASokerS. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng2016; 113: 2020–32.
69.
MatanoMDateSShimokawaMTakanoAFujiiMOhtaYWatanabeTKanaiTSatoT. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med2015; 21: 256–62.
70.
LiMSuzukiKKimNYLiuGHIzpisua BelmonteJC. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J Biol Chem2014; 289: 4594–9.
71.
RogozAReisBSKarssemeijerRAMucidaD. A 3-D enteroid-based model to study T-cell and epithelial cell interaction. J Immunol Meth2015; 421: 89–95.
72.
ShaffieySAJiaHKeaneTCostelloCWassermanDQuidgleyMDzikiJBadylakSSodhiCPMarchJCet al.Intestinal stem cell growth and differentiation on a tubular scaffold with evaluation in small and large animals. Regen Med2016; 11: 45–61.
73.
WorkmanMJMaheMMTrisnoSPolingHMWatsonCLSundaramNChangCFSchiesserJAubertPStanleyEGet al.Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med2017; 23: 49–59.
74.
KimHJHuhDHamiltonGIngberDE. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip2012; 12: 2165–74.
75.
AttayekPJAhmadAAWangYWilliamsonISimsCEMagnessSTAllbrittonNL. In vitro polarization of colonoids to create an intestinal stem cell compartment. PLoS One2016; 11: e0153795–e0153795.
